To evaluate the single dose pharmacokinetic profile of Viracept pediatric powder formulation
administered to HIV infected or exposed children and infants (0 to 13 years of age). An
evaluation of the relative bioavailability of the pediatric powder formulation vs. a
standard tablet formulation in older children (7 to 13 years of age) will also be conducted.
This is a study of the safety, tolerability and pharmacokinetics of a Viracept pediatric
powder formulation with milk or formula. First a single dose will be administered. After the
patient population is divided into 4 groups by age, an optimal dose will be determined for
each group. This optimal dose will be given 3 times a day for a 6 week primary observation
period, plus an optional 6 month extension.
NOTE: During the single dose portion of this study, patients may be untreated or may
continue treatment with their current nucleoside antiretroviral therapy. During multiple
dose administration of Viracept, antiretroviral therapy will be intensified by either adding
or modifying therapy. Antiretroviral therapies will be limited to those currently licensed
including zidovudine, lamivudine, stavudine, didanosine or zalcitabine.
Administration of Pneumocystis carinii pneumonia prophylaxis according to CDC guidelines
will be permitted.
Patients must have:
- For children >= 3 months to 13 years of age:
- HIV infection. For children <3 months of age:
- HIV infection or exposure.
- Newborns must have birth weight >= 2500 gm.
- Absence at screen of any serious or unstable medical conditions.
- Parent or guardian able to give written informed consent and willing to comply with
Patients with any of the following symptoms or conditions are excluded:
- Children with HIV associated malignancy requiring chemotherapy.
- Children with clinical or laboratory assessments greater than Grade 1 in the Toxicity
Table at the time of the screening.
- Protease inhibitors.
- Patients who have taken investigational agents, immunomodulators, HIV-1 vaccines,
glucocorticoids or unconventional therapies within one month prior to the day 0 of
the study must be evaluated to determine the impact of these treatments on the study.
Patients may be included or excluded on a case to case basis.